Tyrosine kinase inhibitors in the treatment of leptomeningeal carcinomatosis
Cell Biology International · 2024
DOI: 10.1002/cbin.12230 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cell Biology International, 2024. Verfasst von Hanyu Ni und 7 weiteren Autor:innen. Beteiligte Einrichtung: Brain and Nerve Research Laboratory, Department of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Meningeal Carcinomatosis. Die Arbeit nennt 126 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Boxi Youth Natural Science Foundation.
Abstract (Originalsprache)
Leptomeningeal carcinomatosis (LMC) is a devastating complication of advanced cancers, such as lung cancer and breast cancer, which is usually indicative of a poor prognosis. The current treatments for LMC include palliative care, with others aiming to prolong survival and relieve neurological symptoms. Traditional treatments for LMC include radiotherapy, systemic chemotherapy, and intrathecal injection. Furthermore, the application of molecularly targeted agents, such as antiepidermal growth factor receptor (anti‐EGFR), antihuman epidermal growth factor receptor 2 (anti‐HER2), and anti‐PD‐1 monoclonal antibody, have prolonged the survival of LMC patients. Targeted therapy with tyrosine kinase inhibitors has also been proven to be an effective treatment. Tyrosine kinases can be overactive or expressed at high levels in some cancer cells; therefore, the use of tyrosine kinase inhibitors may prevent the activation of tumor‐related pathways, preventing cancer cell growth. The EGFR family are cell surface receptors directly related to tumor occurrence with tyrosine kinase activity; it is the most widely used target for tyrosine kinase inhibitors in the treatment of LMC. In this review, we introduced the clinical manifestation and diagnostic criteria of LMC, clarified the treatment mechanism of tyrosine kinase inhibitors for LMC with mutations in EGFR, HER2, or anaplastic lymphoma kinase, reviewed the current application of various generation tyrosine kinase inhibitors in patients with LMC, and discussed new clinical trials and the future directions of tyrosine kinase inhibitor therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Brain and Nerve Research Laboratory, Department of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China.
- Suzhou Medical College of Soochow University, Suzhou, Jiangsu Province, China.
Förderung
- National Natural Science Foundation of China
- Boxi Youth Natural Science Foundation
Zitieren
APA
Ni, H., Wang, Z., Tang, Y., Lu, J., Zhu, Z., Qiu, Y., Chen, Z., & Wang, Z. (2024). Tyrosine kinase inhibitors in the treatment of leptomeningeal carcinomatosis. Cell Biology International. https://doi.org/10.1002/cbin.12230
Vancouver
Ni H, Wang Z, Tang Y, Lu J, Zhu Z, Qiu Y, et al. Tyrosine kinase inhibitors in the treatment of leptomeningeal carcinomatosis. Cell Biology International. 2024. doi:10.1002/cbin.12230
BibTeX
@article{Ni2024,
author = {Ni, Hanyu and Wang, Zilan and Tang, Yanbing and Lu, Jiaye and Zhu, Zixiang and Qiu, Youjia and Chen, Zhouqing and Wang, Zhong},
title = {Tyrosine kinase inhibitors in the treatment of leptomeningeal carcinomatosis},
journal = {Cell Biology International},
year = {2024},
doi = {10.1002/cbin.12230}
}
EUVIMED